Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: A retrospective study

World Journal of Surgical Oncology

Volumn 13, Issue 1, 2015, Pages

  Hongo, Kumiko ^a   Kazama, Shinsuke ^a   Tsuno, Nelson H ^a   Ishihara, Soichiro ^a   Sunami, Eiji ^a   Kitayama, Joji ^a   Watanabe, Toshiaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chemoradiotherapy; High mobility group box 1 (HMGB1); Immunohistochemistry; Lower rectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PROTEIN EXPRESSION; RECTUM CANCER; RETROSPECTIVE STUDY; TUMOR INVASION; VASCULAR TUMOR; ADENOCARCINOMA, MUCINOUS; CANCER GRADING; CANCER STAGING; DRUG RESISTANCE; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREOPERATIVE CARE; PROGNOSIS; RADIATION TOLERANCE; RECTAL NEOPLASMS; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; BIOMARKERS, TUMOR; CHEMORADIOTHERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HMGB1 PROTEIN; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; RADIATION TOLERANCE; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84928709219     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-13-7     Document Type: Article

References (49)

1. Czura CJ, Wang H, Tracey KJ: Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001, 7:315-21.
2. Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-42. 10.1038/nri1594.
3. Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, et al.: New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 2001, 20:4337-40. 10.1093/emboj/20.16.4337.
4. Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, et al.: High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007, 30:596-606. 10.1097/CJI.0b013e31804efc76.
5. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al.: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007, 13:2836-48. 10.1158/1078-0432.CCR-06-1953.
6. Tang D, Kang R, Zeh HJ 3rd, Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta 2010, 1799:131-40. 10.1016/j.bbagrm.2009.11.014.
7. Erlandsson Harris H, Andersson U: Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 2004, 34:1503-12. 10.1002/eji.200424916.
8. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-5. 10.1038/nature00858.
9. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al.: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101:2652-60. 10.1182/blood-2002-05-1300.
10. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, et al.: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004, 101:296-301. 10.1073/pnas.2434651100.
11. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, et al.: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006, 290:C917-24.
12. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, et al.: HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004, 5:825-30. 10.1038/sj.embor.7400205.
13. Wang H, Yang H, Tracey KJ: Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004, 255:320-31. 10.1111/j.1365-2796.2003.01302.x.
14. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al.: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. Journal Exp Med 2005, 201:1135-43. 10.1084/jem.20042614.
15. Tang D, Kang R, Cao L, Zhang G, Yu Y, Xiao W, et al.: A pilot study to detect high mobility group box 1 and heat shock protein 72 in cerebrospinal fluid of pediatric patients with meningitis. Crit Care Med 2008, 36:291-5. 10.1097/01.CCM.0000295316.86942.CE.
16. Qi ML, Tagawa K, Enokido Y, Yoshimura N, Wada Y, Watase K, et al.: Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases. Nat Cell Biol 2007, 9:402-14. 10.1038/ncb1553.
17. Enokido Y, Yoshitake A, Ito H, Okazawa H: Age-dependent change of HMGB1 and DNA double-strand break accumulation in mouse brain. Biochem Biophys Res Commun 2008, 376:128-33. 10.1016/j.bbrc.2008.08.108.
18. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al.: RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009, 7:17. 10.1186/1479-5876-7-17.
19. Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, et al.: Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004, 164:441-9. 10.1083/jcb.200304135.
20. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-51. 10.1126/science.285.5425.248.
21. Yu W, Kim J, Ossowski L: Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997, 137:767-77. 10.1083/jcb.137.3.767.
22. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al.: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-60. 10.1038/35012626.
23. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H: Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005, 64:92-100. 10.1002/pros.20219.
24. Volp K, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, Gottel D, et al.: Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006, 55:234-42. 10.1136/gut.2004.062729.
25. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, et al.: Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 2003, 63:2188-93.
26. Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G: Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010, 136:677-84. 10.1007/s00432-009-0706-1.
27. Moriwaka Y, Luo Y, Ohmori H, Fujii K, Tatsumoto N, Sasahira T, et al.: HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology 2010, 77:17-23. 10.1159/000272950.
28. Yang H, Wang H, Czura CJ, Tracey KJ: The cytokine activity of HMGB1. J Leukoc Biol 2005, 78:1-8. 10.1189/jlb.1104648.
29. Huttunen HJ, Fages C, Rauvala H: Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999, 274:19919-24. 10.1074/jbc.274.28.19919.
30. Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A: Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 2005, 26:293-301.
31. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, et al.: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010, 29:5299-310. 10.1038/onc.2010.261.
32. Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, et al.: HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 2012, 72:230-8. 10.1158/0008-5472.CAN-11-2001.
33. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al.: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-9. 10.1038/nm1622.
34. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, et al.: HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009, 6:e10. 10.1371/journal.pmed.1000010.
35. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW: Colorectal cancer. Lancet 2005, 365:153-65. 10.1016/S0140-6736(05)17706-X.
36. Belluco C, De Paoli A, Canzonieri V, Sigon R, Fornasarig M, Buonadonna A, et al.: Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies. Ann Surg Oncol 2011, 18:3686-93. 10.1245/s10434-011-1822-0.
37. Sobin LH, Gospodarowicz MK, Wittekind C: TNM Classification of Malignant Tumors. 7th edition. Hoboken, NJ, United States: Wiley-Blackwell; 2009.
38. Organnization WH: International Classification of Diseases for Oncology. 3rd edition. International Association of Cancer Registries: Lyon, France; 2000.
39. Rectum JS, Cot C: General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum, and Anus. Tokyo, Japan: Kanehara & Co; 2006.
40. Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5.
41. Mantovani A: Cancer: inflaming metastasis. Nature 2009, 457:36-7.
42. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008, 454:436-44. 10.1038/nature07205.
43. Vakkila J, Lotze MT: Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004, 4:641-8. 10.1038/nri1415.
44. Sasahira T, Kirita T, Oue N, Bhawal UK, Yamamoto K, Fujii K, et al.: High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 2008, 99:1806-12.
45. Yuan F, Gu L, Guo S, Wang C, Li GM: Evidence for involvement of HMGB1 protein in human DNA mismatch repair. J Biol Chem 2004, 279:20935-40. 10.1074/jbc.M401931200.
46. Tang D, Kang R, Livesey KM, Kroemer G, Billiar TR, Van Houten B, et al.: High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab 2011, 13:701-11. 10.1016/j.cmet.2011.04.008.
47. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, et al.: HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011, 25:23-31. 10.1038/leu.2010.225.
48. Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A: Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 2008, 68:1485-94. 10.1158/0008-5472.CAN-07-0562.
49. Levine B: Cell biology: autophagy and cancer. Nature 2007, 446:745-7. 10.1038/446745a.